Oct 1, 2026, 8:03 AM EDT · 2 days ago 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
Sep 3, 2026, 8:04 AM EDT · 4 weeks ago 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
Aug 14, 2026, 3:47 PM EDT · 7 weeks ago 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-07-30T18:35:43.000Z · 2 months ago 60 Degrees Pharmaceuticals to sell shares and warrants in private placement
Jul 30, 2026, 2:23 PM EDT · 2 months ago 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
2026-07-29T21:15:29.000Z · 2 months ago 60 Degrees Pharma babesiosis interim readout planned by October 6
Jul 29, 2026, 4:03 PM EDT · 2 months ago 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Jul 8, 2026, 8:01 AM EDT · 2 months ago 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
2026-07-01T12:25:16.000Z · 3 months ago 60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study
Jul 1, 2026, 8:02 AM EDT · 3 months ago 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
2026-06-11T13:01:09.000Z · 3 months ago 60 Degrees executes patent licensing agreement with Florida State
Jun 11, 2026, 8:03 AM EDT · 3 months ago 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
2026-05-26T14:57:43.000Z · 4 months ago 60 Degrees announces early enrollment of first patient in trial of tafenoquine
May 26, 2026, 8:02 AM EDT · 4 months ago 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
2026-05-20T16:00:11.000Z · 4 months ago H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending
2026-05-20T15:55:36.000Z · 4 months ago 60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
May 15, 2026, 8:42 AM EDT · 4 months ago 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
2026-04-15T12:37:07.000Z · 5 months ago 60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website
2026-03-18T12:12:35.000Z · 6 months ago 60 Degrees submits NDIN to FDA for Australian Chestnut Extract
Mar 18, 2026, 8:01 AM EDT · 6 months ago 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
2026-03-11T11:30:55.000Z · 6 months ago 60 Degrees reports all patients cured of babesiosis after tafenoquine treatment
Mar 11, 2026, 7:24 AM EDT · 6 months ago 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
2026-02-02T13:21:06.000Z · 8 months ago 60 Degrees expands access to Arakoda with GoodRx partnership GDRX
Feb 2, 2026, 8:01 AM EST · 8 months ago 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
2026-01-27T16:30:17.000Z · 8 months ago 60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split
2026-01-22T14:15:44.000Z · 8 months ago Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today
2026-01-22T13:27:13.000Z · 8 months ago 60 Degrees Pharmaceuticals announces partnership with Runway Health
2026-01-15T13:21:52.000Z · 8 months ago 60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split
Jan 15, 2026, 8:01 AM EST · 8 months ago 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
Dec 29, 2025, 8:01 AM EST · 9 months ago 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Dec 11, 2025, 8:01 AM EST · 9 months ago 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
Nov 21, 2025, 8:01 AM EST · 10 months ago 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
Nov 13, 2025, 1:51 PM EST · 10 months ago 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
Oct 15, 2025, 7:14 AM EDT · 11 months ago 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
Oct 9, 2025, 7:04 AM EDT · 11 months ago 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
Sep 3, 2025, 8:02 AM EDT · 1 year ago 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Aug 21, 2025, 8:31 AM EDT · 1 year ago 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
Aug 19, 2025, 8:54 AM EDT · 1 year ago 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Aug 13, 2025, 4:14 PM EDT · 1 year ago 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
Jul 16, 2025, 4:01 PM EDT · 1 year ago 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
Jul 15, 2025, 9:10 AM EDT · 1 year ago 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
Jul 15, 2025, 7:01 AM EDT · 1 year ago 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
Jun 4, 2025, 8:56 AM EDT · 1 year ago 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
Jun 3, 2025, 8:49 AM EDT · 1 year ago Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
May 15, 2025, 4:31 PM EDT · 1 year ago 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
Apr 22, 2025, 8:44 AM EDT · 1 year ago Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
Apr 10, 2025, 8:31 AM EDT · 1 year ago Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
Apr 8, 2025, 8:31 AM EDT · 1 year ago Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
Feb 21, 2025, 9:00 AM EST · 1 year ago 60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV FTHM
Feb 20, 2025, 10:36 AM EST · 1 year ago 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
Feb 11, 2025, 12:59 PM EST · 1 year ago Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
Feb 6, 2025, 2:07 PM EST · 1 year ago 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Feb 5, 2025, 9:22 AM EST · 1 year ago 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jan 30, 2025, 2:20 PM EST · 1 year ago 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jan 28, 2025, 8:01 AM EST · 1 year ago 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Jan 8, 2025, 8:02 AM EST · 1 year ago 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Dec 23, 2024, 8:57 AM EST · 1 year ago Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Dec 11, 2024, 8:56 AM EST · 1 year ago 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Dec 2, 2024, 4:05 PM EST · 1 year ago VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Nov 22, 2024, 9:00 AM EST · 1 year ago 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV CANF
Nov 14, 2024, 2:31 PM EST · 1 year ago 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
Oct 3, 2024, 9:02 AM EDT · 2 years ago 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
Sep 4, 2024, 8:00 AM EDT · 2 years ago 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Aug 28, 2024, 2:48 PM EDT · 2 years ago 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements